(Q48000427)

7 February 2018

editorial

0 references

title

Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting. (English)

1 reference

7 February 2018

1 reference

metastatic colon cancer

1 reference

3

1 reference

7 February 2018

Marc Peeters

5

1 reference

7 February 2018

author name string

Christian Rolfo

1

1 reference

7 February 2018

Antonio Russo

2

1 reference

7 February 2018

Giuseppe Bronte

4

1 reference

7 February 2018

language of work or name

English

0 references

publication date

15 July 2013

1 reference

7 February 2018

Expert Opinion on Therapeutic Targets

published in

1 reference

7 February 2018

volume

17

1 reference

7 February 2018

issue

8

1 reference

7 February 2018

page(s)

869-871

1 reference

7 February 2018

A genetic model for colorectal tumorigenesis

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Biologic therapies in the metastatic colorectal cancer treatment continuum--applying current evidence to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Analysis of circulating tumor DNA to confirm somatic KRAS mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2013.818135

10.1517/14728222.2013.818135

21 January 2018

Identifiers

DOI

1 reference

7 February 2018

PubMed ID

23848525

1 reference

7 February 2018